Login to Your Account



Potential $285M: Ipsen and Active Biotech in TASQ Deal

By Cormac Sheridan


Tuesday, April 19, 2011
Active Biotech AB is banking an up-front payment of $35.6 million and could get $249.4 million more on the back of a partnering deal with Ipsen SA on its Phase III cancer drug tasquinimod (TASQ).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription